Founded in 2012, Avidity is developing a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates to treat ...

Novartis AG agreed to buy Avidity Biosciences Inc. in a $12 billion deal that’s the Swiss drugmaker’s biggest acquisition in ...

Shares of Novartis fell 1% on Monday following news of the company's plans to acquire U.S. biotech Avidity Biosciences for ...

Swiss drugmaker Novartis on Sunday said it agreed to acquire U.S. biotech firm Avidity Biosciences for about $12 billion in ...

(Oct 27): Novartis AG agreed to buy biotechnology company Avidity Biosciences Inc in a deal valued at US$12 billion, making ...

The Swiss drugmaker on Sunday said it agreed to acquire U.S. biotech firm Avidity Biosciences for about $12 billion in cash ...

The Swiss pharma is paying $12 billion for Avidity Biosciences and its three late-stage antibody oligonucleotide conjugates.

The Swiss pharmaceutical company says the purchase would complement its existing pipeline of treatments for neuromuscle ...

NEW YORK] Novartis agreed to buy biotechnology company Avidity Biosciences in a deal that values it at US$12 billion, ...

The chances somebody did not copy and paste elements of the 2025 HSC exam from a West Australian exam are more than one in a ...

Swiss drugmaker Novartis on Monday defended its $12 billion deal to acquire Avidity Biosciences ahead of the U.S. firm ...

Novartis to acquire Avidity Biosciences for $12 billion to strengthen rare disease therapies and offset looming patent ...